LGND

104.82

0.30% -0.32

Vorhandelsmarkt: 104.44 -0.38 -0.36%

Ligand Pharmaceuticals Inc (LGND)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$105.14

Offen:

$104.95

24-Stunden-Volumen:

97,782

Relative Volume:

0.94

Marktkapitalisierung:

$2.02B

Einnahmen:

$152.42M

Nettoeinkommen (Verlust:

$45.24M

KGV:

41.76

EPS:

2.51

Netto-Cashflow:

$6.97M

1W Leistung:

-4.44%

1M Leistung:

-14.24%

6M Leistung:

+3.42%

1J Leistung:

+42.42%

1-Tages-Spanne:

$102.50

$107.49

1-Wochen-Bereich:

$102.50

$112.49

52-Wochen-Spanne:

$67.72

$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Firmenname

Ligand Pharmaceuticals Inc

Sektor

Healthcare (1165)

Branche

Biotechnology (681)

Telefon

858-550-7500

Adresse

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Mitarbeiter

Twitter

@Ligand_LGND

Nächster Verdiensttermin

2025-02-18

Neueste SEC-Einreichungen

LGND's Discussions on Twitter

Vergleichen Sie LGND mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LGND Ligand Pharmaceuticals Inc	104.82	2.02B	152.42M	45.24M	6.97M	2.51
VRTX Vertex Pharmaceuticals Inc	484.74	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	617.00	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	567.09	34.59B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	255.76	33.10B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	271.04	29.15B	3.81B	-644.79M	-669.77M	-6.24

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-03	Eingeleitet	Oppenheimer	Outperform
2024-07-30	Eingeleitet	RBC Capital Mkts	Outperform
2021-04-14	Fortgesetzt	Stephens	Overweight
2021-02-04	Bestätigt	H.C. Wainwright	Buy
2020-10-06	Eingeleitet	Barclays	Overweight
2020-03-24	Herabstufung	Argus	Buy → Hold
2020-03-10	Eingeleitet	Guggenheim	Neutral
2020-02-06	Eingeleitet	The Benchmark Company	Buy
2019-09-19	Hochstufung	Barclays	Equal Weight → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-03	Bestätigt	H.C. Wainwright	Buy
2019-03-06	Bestätigt	H.C. Wainwright	Buy
2018-10-29	Hochstufung	ROTH Capital	Neutral → Buy
2018-10-02	Bestätigt	H.C. Wainwright	Buy
2018-09-11	Bestätigt	Argus	Buy
2018-08-17	Eingeleitet	Goldman	Neutral
2018-08-08	Herabstufung	ROTH Capital	Buy → Neutral
2018-06-21	Eingeleitet	Argus	Buy
2017-12-27	Bestätigt	H.C. Wainwright	Buy
2017-09-05	Fortgesetzt	H.C. Wainwright	Buy
2016-10-05	Bestätigt	H.C. Wainwright	Buy
2016-08-05	Herabstufung	Deutsche Bank	Hold → Sell
2016-03-11	Eingeleitet	Sidoti	Buy
2016-03-03	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten

Mar 31, 2025

PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView

Mar 31, 2025

Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 31, 2025

Mar 30, 2025

HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 30, 2025

Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 30, 2025

Mar 26, 2025

Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 26, 2025

Mar 20, 2025

Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 20, 2025

Mar 19, 2025

Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire

Mar 19, 2025

Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 19, 2025

Mar 18, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World

Mar 18, 2025

US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 18, 2025

Mar 16, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World

Mar 16, 2025

Mar 13, 2025

Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 13, 2025

Mar 12, 2025

Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 12, 2025

Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus

Mar 12, 2025

Mar 11, 2025

Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 11, 2025

Mar 07, 2025

CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks

Mar 07, 2025

Mar 06, 2025

Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada

Mar 06, 2025

Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com

Mar 06, 2025

Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 06, 2025

Mar 05, 2025

Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 05, 2025

Mar 04, 2025

Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Mar 04, 2025

Mar 03, 2025

LGND: First Steps into Cell & Gene Therapy - Research Tree

Mar 03, 2025

Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan

Mar 03, 2025

Ligand to Participate in March Investor Conferences - Yahoo Finance

Mar 03, 2025

Mar 02, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World

Mar 02, 2025

Mar 01, 2025

Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Mar 01, 2025

Feb 28, 2025

Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks

Feb 28, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat

Feb 28, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat

Feb 28, 2025

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com

Feb 28, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com

Feb 28, 2025